Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Spain flag Spain · Delayed Price · Currency is EUR
59.30
-1.20 (-1.98%)
Oct 7, 2025, 3:45 PM CET
-1.98%
Market Cap3.09B
Revenue (ttm)749.00M
Net Income (ttm)132.27M
Shares Out51.15M
EPS (ttm)2.59
PE Ratio23.38
Forward PE20.73
Dividend0.94 (1.53%)
Ex-Dividend DateJul 14, 2025
Volume96,210
Average Volume134,131
Open58.75
Previous Close60.50
Day's Range58.00 - 60.00
52-Week Range45.52 - 80.20
Beta0.50
RSI53.80
Earnings DateNov 6, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Sector Healthcare
Founded 1946
Employees 2,197
Stock Exchange Madrid Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements